Schering-Plough effects mask Merck & Co's underlying profit growth
This article was originally published in Scrip
Merck & Co saw its net profit attributable to the company tumble from $1.43 billion to $299 million in the first full quarter following the closure of its merger with Schering-Plough. However, when purchase accounting, restructuring and merger-related costs are stripped out, net profit stood at $2.61 billion. EPS fell from $0.67 to $0.09, although when adjusted the figure was $0.83, up from $0.74 a year before.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.